Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mo | MiNK Therapeutics receives NIH grant for GvHD therapy | 2 | Investing.com | ||
Mo | MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients | 2 | GlobeNewswire (USA) | ||
15.05. | MiNK Therapeutics outlines near-term partnering proposals and reduced cash burn as company advances iNKT programs | 2 | Seeking Alpha | ||
15.05. | MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress | 155 | GlobeNewswire (Europe) | Clinical data builds with CR in testicular cancer, enrollment in Phase 2 gastric trial, and new data in PD-1-resistant tumors Near-term capital transactions poised to bolster liquidity NEW YORK... ► Artikel lesen | |
15.05. | MiNK Therapeutics GAAP EPS of -$0.70 misses by $0.09 | 1 | Seeking Alpha | ||
15.05. | MiNK Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
05.05. | MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report | 2 | GlobeNewswire (USA) | ||
18.03. | MiNK Therapeutics, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
MINK THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
18.03. | MiNK Therapeutics, Inc. Q4 Loss Decreases, But Misses Estimates | - | RTTNews | ||
18.03. | MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress | 205 | GlobeNewswire (Europe) | NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf invariant natural... ► Artikel lesen | |
18.03. | MiNK Therapeutics GAAP EPS of -$0.62 misses by $0.12 | - | Seeking Alpha | ||
18.03. | MiNK Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
25.02. | MiNK Therapeutics stock target soars to $35 at H.C. Wainwright | 2 | Investing.com | ||
24.02. | MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting | 181 | GlobeNewswire (Europe) | NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf invariant natural... ► Artikel lesen | |
20.02. | MiNK Therapeutics regains Nasdaq compliance | 1 | Seeking Alpha | ||
20.02. | MiNK Therapeutics erfüllt wieder Nasdaq-Anforderungen | 1 | Investing.com Deutsch | ||
20.02. | MiNK Therapeutics Regains Full Compliance with Nasdaq Listing Requirements | 159 | GlobeNewswire (Europe) | NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic... ► Artikel lesen | |
12.02. | MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting | 1 | GlobeNewswire (USA) | ||
28.01. | XFRA 6Q40: AUSSETZUNG/SUSPENSION | 196 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILMINK THERAP.NEW... ► Artikel lesen | |
28.01. | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA 28.01.2025 | 354 | Xetra Newsboard | The following instruments on XETRA do have their first trading 28.01.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 28.01.2025
Aktien
1 IT0005622581 Vivenda Group S.p.A.
2... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIOLINERX | 3,283 | -100,00 % | Why BioLineRx Ltd. (BLRX) Surged Last Week | ||
TRANSCODE THERAPEUTICS | 7,250 | -0,34 % | TransCode Therapeutics, Inc.: TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported | 15 patients treated across four escalating dose levels of TTX-MC138
No significant safety or dose limiting toxicities reported
10 patients remain on study with... ► Artikel lesen | |
SILEXION THERAPEUTICS | 0,945 | +3,80 % | Silexion Therapeutics Corp: Silexion Therapeutics Announces Groundbreaking Preclinical Results: SIL204 Shows Strong Efficacy in Pancreatic, Colorectal, and Lung Cancers | GRAND CAYMAN, Cayman Islands, May 29, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference... ► Artikel lesen | |
PSYENCE BIOMEDICAL | 5,590 | +9,18 % | Psyence Biomedical Ltd.: Psyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical Trial | New York, New York--(Newsfile Corp. - May 27, 2025) - Psyence BioMed (NASDAQ: PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company developing nature-derived psilocybin therapies for... ► Artikel lesen | |
PHATHOM PHARMACEUTICALS | 8,920 | +90,19 % | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | ||
AVIDITY BIOSCIENCES | 36,240 | +1,83 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, May 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... ► Artikel lesen | |
QIAGEN | 40,060 | -0,55 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Qiagen von 47 auf 50 US-Dollar angehoben und die Einstufung auf "Buy" belassen. Analyst Jan Koch zog in seinem am Dienstag... ► Artikel lesen | |
ARCELLX | 68,10 | +2,81 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
ARCUTIS BIOTHERAPEUTICS | 14,370 | +6,37 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
RECURSION PHARMACEUTICALS | 5,485 | +20,02 % | Recursion Pharmaceuticals shares surge on AI model release | ||
TARSUS PHARMACEUTICALS | 43,920 | -0,39 % | Oppenheimer assumes Tarsus stock at outperform on strong sales | ||
BIONTECH | 95,35 | +0,05 % | BioNTech SE: BioNTech und Bristol Myers Squibb geben globale strategische Partnerschaft zur gemeinsamen Entwicklung und Kommerzialisierung des bispezifischen Antikörperkandidaten BNT327 in einer Vielzahl solider Tumorarten bekannt | BioNTechs bispezifischer PD-L1xVEGF-Antikörper BNT327 ist ein Immuntherapiekandidat in der fortgeschrittenen klinischen Entwicklung, der das Potenzial hat für verschiedene Tumorarten einen neuen Behandlungsstandard... ► Artikel lesen | |
VERA THERAPEUTICS | 22,760 | -25,69 % | Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy | Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared... ► Artikel lesen | |
MOONLAKE IMMUNOTHERAPEUTICS | 46,880 | -3,99 % | ROUNDUP/Aktien New York: Knappes Plus - Gelassenheit trotz Zoll-Unruhen | NEW YORK (dpa-AFX) - Die US-Börsen haben am Dienstag knappe Kursgewinne erzielt. Die jüngst wieder aufflackernden, internationalen Handelsstreitigkeiten wegen der amerikanischen Zollpolitik scheinen... ► Artikel lesen | |
EDGEWISE THERAPEUTICS | 15,240 | +2,83 % | RBC Capital behält Outperform-Rating für Edgewise Therapeutics-Aktie bei |